{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T13:47:10Z","timestamp":1784814430540,"version":"3.55.0"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T00:00:00Z","timestamp":1748908800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T00:00:00Z","timestamp":1748908800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key R&D Program of China","doi-asserted-by":"crossref","award":["2023YFC3403200"],"award-info":[{"award-number":["2023YFC3403200"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82472774"],"award-info":[{"award-number":["82472774"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"DOI":"10.1007\/s00345-025-05728-9","type":"journal-article","created":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T06:32:00Z","timestamp":1748932320000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Liquid biopsy for promoter methylation in prostate cancer: a promising non-invasive diagnostic weapon"],"prefix":"10.1007","volume":"43","author":[{"given":"Zeyu","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yize","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaxiong","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianyanling","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuanji","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dazhou","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0617-9286","authenticated-orcid":false,"given":"Jianzhong","family":"Ai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,3]]},"reference":[{"key":"5728_CR1","doi-asserted-by":"publisher","unstructured":"Sandhu S, Moore CM, Chiong E et al (2021) Prostate cancer. Lancet 398:1075. https:\/\/doi.org\/10.1016\/s0140-6736(21)00950-8","DOI":"10.1016\/s0140-6736(21)00950-8"},{"key":"5728_CR2","doi-asserted-by":"publisher","unstructured":"Carlsson SV, Vickers AJ (2020) Screening for prostate Cancer. Med Clin North Am 104:1051. https:\/\/doi.org\/10.1016\/j.mcna.2020.08.007","DOI":"10.1016\/j.mcna.2020.08.007"},{"key":"5728_CR3","doi-asserted-by":"publisher","unstructured":"Siegel RL, Miller KD, Fuchs HE et al (2022) Cancer statistics, 2022. CA Cancer J Clin 72:7\u201333. https:\/\/doi.org\/10.3322\/caac.21708","DOI":"10.3322\/caac.21708"},{"key":"5728_CR4","doi-asserted-by":"publisher","unstructured":"Gandaglia G, Leni R, Bray F et al (2021) Epidemiology and prevention of prostate Cancer. Eur Urol Oncol. 4:877\u2013\u200992. https:\/\/doi.org\/10.1016\/j.euo.2021.09.006","DOI":"10.1016\/j.euo.2021.09.006"},{"key":"5728_CR5","doi-asserted-by":"publisher","unstructured":"Lowrance W, Dreicer R, Jarrard DF et al (2023) Updates to advanced prostate cancer: AUA\/SUO guideline (2023). J Urol 209:1082\u20131090. https:\/\/doi.org\/10.1097\/ju.0000000000003452","DOI":"10.1097\/ju.0000000000003452"},{"key":"5728_CR6","doi-asserted-by":"publisher","unstructured":"Cornford P, van den Bergh RCN, Briers E et al (2024) EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate Cancer-2024 update. Part I: screening, diagnosis, and local treatment with curative intent. Eur Urol 86:148\u2013163. https:\/\/doi.org\/10.1016\/j.eururo.2024.03.027","DOI":"10.1016\/j.eururo.2024.03.027"},{"key":"5728_CR7","doi-asserted-by":"publisher","unstructured":"Stamey TA, Yang N, Hay AR et al (1987) Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 317:909\u2013916. https:\/\/doi.org\/10.1056\/nejm198710083171501","DOI":"10.1056\/nejm198710083171501"},{"key":"5728_CR8","doi-asserted-by":"publisher","unstructured":"Georgiou LA, Scarbrough BE (2024) PSA screening for prostate cancer in the united states: 30 years of controversy. J Public Health Policy..45:552\u2013\u200961. https:\/\/doi.org\/10.1057\/s41271-024-00502-4","DOI":"10.1057\/s41271-024-00502-4"},{"key":"5728_CR9","unstructured":"Aubry W, Lieberthal R, Willis A et al (2013) Budget impact model: epigenetic assay can help avoid unnecessary repeated prostate biopsies and reduce healthcare spending. Am Health Drug Benefits 6:15\u201324"},{"key":"5728_CR10","doi-asserted-by":"publisher","unstructured":"Groen L, Schalken J (2022) Liquid biopsy for prostate and bladder cancer: progress and pitfalls. Eur Urol Focus 8. https:\/\/doi.org\/10.1016\/j.euf.2022.08.013","DOI":"10.1016\/j.euf.2022.08.013"},{"key":"5728_CR11","doi-asserted-by":"publisher","unstructured":"Crocetto F, Russo G, Di Zazzo E et al (2022) Liquid biopsy in prostate Cancer Management-Current challenges and future perspectives. Cancers (Basel) 14. https:\/\/doi.org\/10.3390\/cancers14133272","DOI":"10.3390\/cancers14133272"},{"key":"5728_CR12","doi-asserted-by":"publisher","unstructured":"Yang J, Xu J, Wang W et al (2023) Epigenetic regulation in the tumor microenvironment: molecular mechanisms and therapeutic targets. Signal Transduct Target Ther. https:\/\/doi.org\/10.1038\/s41392-023-01480-x","DOI":"10.1038\/s41392-023-01480-x"},{"key":"5728_CR13","doi-asserted-by":"publisher","unstructured":"Han Z, Yi X, Li J et al (2023) RNA m(6)A modification in prostate cancer: A new weapon for its diagnosis and therapy. Biochim Biophys Acta Rev Cancer. https:\/\/doi.org\/10.1016\/j.bbcan.2023.188961","DOI":"10.1016\/j.bbcan.2023.188961"},{"key":"5728_CR14","doi-asserted-by":"publisher","unstructured":"Ge R, Wang Z, Montironi R et al (2020) Epigenetic modulations and lineage plasticity in advanced prostate cancer. Ann Oncol 31:470\u2013479. https:\/\/doi.org\/10.1016\/j.annonc.2020.02.002","DOI":"10.1016\/j.annonc.2020.02.002"},{"key":"5728_CR15","doi-asserted-by":"publisher","unstructured":"Herman JG, Baylin SB (2003) Gene Silencing in cancer in association with promoter hypermethylation. N Engl J Med. 349:2042- https:\/\/doi.org\/10.1056\/NEJMra023075","DOI":"10.1056\/NEJMra023075"},{"key":"5728_CR16","doi-asserted-by":"publisher","unstructured":"Hoque MO, Topaloglu O, Begum S et al (2005) Quantitative methylation-specific polymerase chain reaction gene patterns in urine sediment distinguish prostate cancer patients from control subjects. J Clin Oncol 23:6569\u20136575. https:\/\/doi.org\/10.1200\/jco.2005.07.009","DOI":"10.1200\/jco.2005.07.009"},{"key":"5728_CR17","doi-asserted-by":"publisher","unstructured":"Bastian PJ, Palapattu GS, Yegnasubramanian S et al (2008) CpG Island hypermethylation profile in the serum of men with clinically localized and hormone refractory metastatic prostate cancer. J Urol..179:529\u2013\u200934; discussion 34\u2013\u20095 https:\/\/doi.org\/10.1016\/j.juro.2007.09.038","DOI":"10.1016\/j.juro.2007.09.038"},{"key":"5728_CR18","doi-asserted-by":"publisher","unstructured":"Goessl C, M\u00fcller M, Heicappell R et al (2001) DNA-based detection of prostate cancer in blood, urine, and ejaculates. Ann N Y Acad Sci. 945:51- 8. https:\/\/doi.org\/10.1111\/j.1749-6632.2001.tb03863.x","DOI":"10.1111\/j.1749-6632.2001.tb03863.x"},{"key":"5728_CR19","doi-asserted-by":"publisher","unstructured":"Mio C, Damante G (2022) Challenges in promoter methylation analysis in the new era of translational oncology: a focus on liquid biopsy. Biochim Biophys Acta Mol Basis Dis. https:\/\/doi.org\/10.1016\/j.bbadis.2022.166390","DOI":"10.1016\/j.bbadis.2022.166390"},{"key":"5728_CR20","doi-asserted-by":"publisher","unstructured":"Jer\u00f3nimo C, Bastian PJ, Bjartell A et al (2011) Epigenetics in prostate cancer: biologic and clinical relevance. Eur Urol 60:753\u2013766. https:\/\/doi.org\/10.1016\/j.eururo.2011.06.035","DOI":"10.1016\/j.eururo.2011.06.035"},{"key":"5728_CR21","doi-asserted-by":"publisher","unstructured":"Wan X, Wang W, Liu J et al (2014) Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range. BMC Med Res Methodol https:\/\/doi.org\/10.1186\/1471-2288-14-135","DOI":"10.1186\/1471-2288-14-135"},{"key":"5728_CR22","doi-asserted-by":"publisher","unstructured":"Whiting PF, Rutjes AW, Westwood ME et al (2011) QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med..155:529\u2013\u200936. https:\/\/doi.org\/10.7326\/0003-4819-155-8-201110180-00009","DOI":"10.7326\/0003-4819-155-8-201110180-00009"},{"key":"5728_CR23","doi-asserted-by":"publisher","unstructured":"Han Z, Yi X, Li J et al (2024) Efficacy and safety of Adeno-Associated Virus-Based clinical gene therapy for hemophilia: A systematic review and Meta-Analysis. Hum Gene Ther 35:93\u2013103. https:\/\/doi.org\/10.1089\/hum.2023.208","DOI":"10.1089\/hum.2023.208"},{"key":"5728_CR24","unstructured":"Dimitriadis E, Kalogeropoulos T, Velaeti S et al (2013) Study of genetic and epigenetic alterations in urine samples as diagnostic markers for prostate cancer. Anticancer Res 33:191\u2013197"},{"key":"5728_CR25","doi-asserted-by":"publisher","unstructured":"Goessl C, M\u00fcller M, Heicappell R et al (2001) DNA-based detection of prostate cancer in urine after prostatic massage. Urology 58:335\u2013338. https:\/\/doi.org\/10.1016\/s0090-4295(01)01268-7","DOI":"10.1016\/s0090-4295(01)01268-7"},{"key":"5728_CR26","doi-asserted-by":"publisher","unstructured":"Jer\u00f3nimo C, Usadel H, Henrique R et al (2002) Quantitative GSTP1 hypermethylation in bodily fluids of patients with prostate cancer. Urology 60:1131\u20131135. https:\/\/doi.org\/10.1016\/s0090-4295(02)01949-0","DOI":"10.1016\/s0090-4295(02)01949-0"},{"key":"5728_CR27","doi-asserted-by":"publisher","unstructured":"Rogers CG, Gonzalgo ML, Yan G et al (2006) High concordance of gene methylation in post-digital rectal examination and post-biopsy urine samples for prostate cancer detection. J Urol 176:2280\u20132284. https:\/\/doi.org\/10.1016\/j.juro.2006.07.047","DOI":"10.1016\/j.juro.2006.07.047"},{"key":"5728_CR28","unstructured":"Kachakova D, Mitkova A, Popov E et al (2013) Evaluation of the clinical value of the newly identified urine biomarker HIST1H4K for diagnosis and prognosis of prostate cancer in Bulgarian patients. J Buon 18:660\u2013668"},{"key":"5728_CR29","doi-asserted-by":"publisher","unstructured":"Roupr\u00eat M, Hupertan V, Yates DR et al (2007) Molecular detection of localized prostate cancer using quantitative methylation-specific PCR on urinary cells obtained following prostate massage. Clin Cancer Res 13:1720\u20131725. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-06-2467","DOI":"10.1158\/1078-0432.Ccr-06-2467"},{"key":"5728_CR30","doi-asserted-by":"publisher","unstructured":"Bryzgunova OE, Morozkin ES, Yarmoschuk SV et al (2008) Methylation-specific sequencing of GSTP1 gene promoter in circulating\/extracellular DNA from blood and urine of healthy donors and prostate cancer patients. Ann N Y Acad Sci 1137:222\u2013225. https:\/\/doi.org\/10.1196\/annals.1448.039","DOI":"10.1196\/annals.1448.039"},{"key":"5728_CR31","doi-asserted-by":"publisher","unstructured":"Woodson K, O\u2019Reilly KJ, Hanson JC et al (2008) The usefulness of the detection of GSTP1 methylation in urine as a biomarker in the diagnosis of prostate cancer. J Urol.179:508\u2013\u200911; discussion 11\u2013\u20092 https:\/\/doi.org\/10.1016\/j.juro.2007.09.073","DOI":"10.1016\/j.juro.2007.09.073"},{"key":"5728_CR32","doi-asserted-by":"publisher","unstructured":"Vener T, Derecho C, Baden J et al (2008) Development of a multiplexed urine assay for prostate cancer diagnosis. Clin Chem 54:874\u2013882. https:\/\/doi.org\/10.1373\/clinchem.2007.094912","DOI":"10.1373\/clinchem.2007.094912"},{"key":"5728_CR33","doi-asserted-by":"publisher","unstructured":"Payne SR, Serth J, Schostak M et al (2009) DNA methylation biomarkers of prostate cancer: confirmation of candidates and evidence urine is the most sensitive body fluid for non-invasive detection. Prostate 69:1257\u20131269. https:\/\/doi.org\/10.1002\/pros.20967","DOI":"10.1002\/pros.20967"},{"key":"5728_CR34","doi-asserted-by":"publisher","unstructured":"Daniunaite K, Jarmalaite S, Kalinauskaite N et al (2014) Prognostic value of RASSF1 promoter methylation in prostate cancer. J Urol 192:1849\u20131855. https:\/\/doi.org\/10.1016\/j.juro.2014.06.075","DOI":"10.1016\/j.juro.2014.06.075"},{"key":"5728_CR35","doi-asserted-by":"publisher","unstructured":"Torres-Ferreira J, Ramalho-Carvalho J, Gomez A et al (2017) MiR-193b promoter methylation accurately detects prostate cancer in urine sediments and miR-34b\/c or miR-129-2 promoter methylation define subsets of clinically aggressive tumors. Mol Cancer. https:\/\/doi.org\/10.1186\/s12943-017-0604-0","DOI":"10.1186\/s12943-017-0604-0"},{"key":"5728_CR36","doi-asserted-by":"publisher","unstructured":"Moreira-Barbosa C, Barros-Silva D, Costa-Pinheiro P et al (2018) Comparing diagnostic and prognostic performance of two-gene promoter methylation panels in tissue biopsies and urines of prostate cancer patients. Clin Epigenetics. https:\/\/doi.org\/10.1186\/s13148-018-0564-2","DOI":"10.1186\/s13148-018-0564-2"},{"key":"5728_CR37","doi-asserted-by":"publisher","unstructured":"Nekrasov KA, Vikarchuk MV, Rudenko EE et al (2019) 6-gene promoter methylation assay is potentially applicable for prostate cancer clinical staging based on urine collection following prostatic massage. Oncol Lett 18:6917\u20136925. https:\/\/doi.org\/10.3892\/ol.2019.11015","DOI":"10.3892\/ol.2019.11015"},{"key":"5728_CR38","unstructured":"Dumache R, Puiu M, Minciu R et al (2012) Retinoic acid receptor \u03b22 (RAR\u03b22): nonivasive biomarker for distinguishing malignant versus benign prostate lesions from bodily fluids. Chirurgia (Bucur) 107:780\u2013784"},{"key":"5728_CR39","doi-asserted-by":"publisher","unstructured":"Crocitto LE, Korns D, Kretzner L et al (2004) Prostate cancer molecular markers GSTP1 and hTERT in expressed prostatic secretions as predictors of biopsy results. Urology 64:821\u2013825. https:\/\/doi.org\/10.1016\/j.urology.2004.05.007","DOI":"10.1016\/j.urology.2004.05.007"},{"key":"5728_CR40","doi-asserted-by":"publisher","unstructured":"Roupr\u00eat M, Hupertan V, Catto JW et al (2008) Promoter hypermethylation in Circulating blood cells identifies prostate cancer progression. Int J Cancer 122:952\u2013956. https:\/\/doi.org\/10.1002\/ijc.23196","DOI":"10.1002\/ijc.23196"},{"key":"5728_CR41","doi-asserted-by":"publisher","unstructured":"Chuang CK, Chu DC, Tzou RD et al (2007) Hypermethylation of the CpG Islands in the promoter region flanking GSTP1 gene is a potential plasma DNA biomarker for detecting prostate carcinoma. Cancer Detect Prev 31:59\u201363. https:\/\/doi.org\/10.1016\/j.cdp.2006.11.001","DOI":"10.1016\/j.cdp.2006.11.001"},{"key":"5728_CR42","doi-asserted-by":"publisher","unstructured":"Ellinger J, Haan K, Heukamp LC et al (2008) CpG Island hypermethylation in cell-free serum DNA identifies patients with localized prostate cancer. Prostate 68:42\u201349. https:\/\/doi.org\/10.1002\/pros.20651","DOI":"10.1002\/pros.20651"},{"key":"5728_CR43","doi-asserted-by":"publisher","unstructured":"Altimari A, Grigioni AD, Benedettini E et al (2008) Diagnostic role of Circulating free plasma DNA detection in patients with localized prostate cancer. Am J Clin Pathol 129:756\u2013762. https:\/\/doi.org\/10.1309\/dbpx1mfnddjbw1fl","DOI":"10.1309\/dbpx1mfnddjbw1fl"},{"key":"5728_CR44","doi-asserted-by":"publisher","unstructured":"Brait M, Banerjee M, Maldonado L et al (2017) Promoter methylation of MCAM, ER\u03b1 and ER\u03b2 in serum of early stage prostate cancer patients. Oncotarget 8:15431\u201315440. https:\/\/doi.org\/10.18632\/oncotarget.14873","DOI":"10.18632\/oncotarget.14873"},{"key":"5728_CR45","doi-asserted-by":"publisher","unstructured":"Wang L, Lin YL, Li B et al (2014) Aberrant promoter methylation of the Cadherin 13 gene in serum and its relationship with clinicopathological features of prostate cancer. J Int Med Res 42:1085\u20131092. https:\/\/doi.org\/10.1177\/0300060514540631","DOI":"10.1177\/0300060514540631"},{"key":"5728_CR46","doi-asserted-by":"publisher","unstructured":"S\u00e1nchez BE, Aguayo A, Mart\u00ednez B et al (2018) Using genetic and epigenetic markers to improve differential diagnosis of prostate Cancer and benign prostatic hyperplasia by noninvasive methods in Mexican patients. Clin Genitourin Cancer 16:e867. https:\/\/doi.org\/10.1016\/j.clgc.2018.02.004","DOI":"10.1016\/j.clgc.2018.02.004"},{"key":"5728_CR47","doi-asserted-by":"publisher","unstructured":"Haldrup C, Pedersen AL, \u00d8gaard N et al (2018) Biomarker potential of ST6GALNAC3 and ZNF660 promoter hypermethylation in prostate cancer tissue and liquid biopsies. Mol Oncol 12:545\u2013560. https:\/\/doi.org\/10.1002\/1878-0261.12183","DOI":"10.1002\/1878-0261.12183"},{"key":"5728_CR48","doi-asserted-by":"publisher","unstructured":"Const\u00e2ncio V, Nunes SP, Moreira-Barbosa C et al (2019) Early detection of the major male cancer types in blood-based liquid biopsies using a DNA methylation panel. Clin Epigenetics. https:\/\/doi.org\/10.1186\/s13148-019-0779-x","DOI":"10.1186\/s13148-019-0779-x"},{"key":"5728_CR49","doi-asserted-by":"publisher","unstructured":"Londra D, Mastoraki S, Bournakis E et al (2021) USP44 promoter methylation in plasma Cell-Free DNA in prostate Cancer. Cancers (Basel) 13. https:\/\/doi.org\/10.3390\/cancers13184607","DOI":"10.3390\/cancers13184607"},{"key":"5728_CR50","doi-asserted-by":"publisher","unstructured":"Lan T, Yin L, Zhang H et al (2021) Diagnostic value of DACT-2 methylation in serum of prostate cancer patients. Ann Palliat Med 10:2421. https:\/\/doi.org\/10.21037\/apm-20-1496","DOI":"10.21037\/apm-20-1496"},{"key":"5728_CR51","unstructured":"Gonzalgo ML, Pavlovich CP, Lee SM et al (2003) Prostate cancer detection by GSTP1 methylation analysis of postbiopsy urine specimens. Clin Cancer Res 9:2673\u20132677"},{"key":"5728_CR52","doi-asserted-by":"publisher","unstructured":"Rashid MM, Alam AK, Habib AK et al (2012) Efficacy of lower cut off value of serum prostate specific antigen in diagnosis of prostate cancer. Bangladesh Med Res Counc Bull 38:90\u201393. https:\/\/doi.org\/10.3329\/bmrcb.v38i3.14333","DOI":"10.3329\/bmrcb.v38i3.14333"},{"key":"5728_CR53","doi-asserted-by":"publisher","unstructured":"AH (2010) Promoter methylation in prostate cancer and its application for the early detection of prostate cancer using serum and urine samples. Biomark Cancer 2:17\u201333. https:\/\/doi.org\/10.4137\/bic.S3187","DOI":"10.4137\/bic.S3187"},{"key":"5728_CR54","doi-asserted-by":"publisher","unstructured":"Ignatiadis M, Sledge GW, Jeffrey SS (2021) Liquid biopsy enters the clinic - implementation issues and future challenges. Nat Rev Clin Oncol 18:297\u2013312. https:\/\/doi.org\/10.1038\/s41571-020-00457-x","DOI":"10.1038\/s41571-020-00457-x"},{"key":"5728_CR55","doi-asserted-by":"publisher","unstructured":"Wang Y, Liu W, Chen Z et al (2024) A noninvasive method for predicting clinically significant prostate cancer using magnetic resonance imaging combined with PRKY promoter methylation level: a machine learning study. BMC Med Imaging. https:\/\/doi.org\/10.1186\/s12880-024-01236-1","DOI":"10.1186\/s12880-024-01236-1"},{"key":"5728_CR56","doi-asserted-by":"publisher","unstructured":"Dai Z, Chen H, Feng K et al (2024) Promoter hypermethylation of Y-chromosome gene PRKY as a potential biomarker for the early diagnosis of prostate cancer. Epigenomics 16:835\u2013850. https:\/\/doi.org\/10.1080\/17501911.2024.2365625","DOI":"10.1080\/17501911.2024.2365625"},{"key":"5728_CR57","doi-asserted-by":"publisher","unstructured":"Saleem MA, Mustafa MS (2024) Promoter hypermethylation of the BRCA1 gene as a novel biomarker for prostate Cancer. Cureus 16:e66467. https:\/\/doi.org\/10.7759\/cureus.66467","DOI":"10.7759\/cureus.66467"},{"key":"5728_CR58","doi-asserted-by":"publisher","unstructured":"Gurioli G, Martignano F, Salvi S et al (2018) GSTP1 methylation in cancer: a liquid biopsy biomarker? Clin Chem Lab Med 56:702\u2013717. https:\/\/doi.org\/10.1515\/cclm-2017-0703","DOI":"10.1515\/cclm-2017-0703"},{"key":"5728_CR59","doi-asserted-by":"publisher","unstructured":"Gupta H, Inoue H, Nakai Y et al (2023) Progressive spreading of DNA methylation in the GSTP1 promoter CpG Island across transitions from precursors to invasive prostate Cancer. Cancer Prev Res (Phila) 16:449\u2013460. https:\/\/doi.org\/10.1158\/1940-6207.Capr-22-0485","DOI":"10.1158\/1940-6207.Capr-22-0485"},{"key":"5728_CR60","doi-asserted-by":"publisher","unstructured":"Mahon KL, Qu W, Lin HM et al (2019) Serum free methylated glutathione S-transferase 1 DNA levels, survival, and response to docetaxel in metastatic, Castration-resistant prostate cancer: post hoc analyses of data from a phase 3 trial. Eur Urol 76:306\u2013312. https:\/\/doi.org\/10.1016\/j.eururo.2018.11.001","DOI":"10.1016\/j.eururo.2018.11.001"},{"key":"5728_CR61","doi-asserted-by":"publisher","unstructured":"Cicatiello AG, Musone M, Imperatore S et al (2025) Circulating MiRNAs in genitourinary cancer: pioneering advances in early detection and diagnosis. J Liquid Biopsy. 8:100296. https:\/\/doi.org\/10.1016\/j.jlb.2025.100296","DOI":"10.1016\/j.jlb.2025.100296"},{"key":"5728_CR62","doi-asserted-by":"publisher","unstructured":"Ferro M, Falagario UG, Barone B et al (2023) Artificial intelligence in the advanced diagnosis of bladder Cancer-Comprehensive literature review and future advancement. Diagnostics (Basel). https:\/\/doi.org\/10.3390\/diagnostics13132308","DOI":"10.3390\/diagnostics13132308"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-025-05728-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-025-05728-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-025-05728-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T13:54:11Z","timestamp":1767966851000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-025-05728-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,3]]},"references-count":62,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5728"],"URL":"https:\/\/doi.org\/10.1007\/s00345-025-05728-9","relation":{},"ISSN":["1433-8726"],"issn-type":[{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,3]]},"assertion":[{"value":"11 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors consent to publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"353"}}